Bristol Myers Squibb Reports Phase 2b Data for Risdiplam in Non-small cell lung cancer

Bristol Myers Squibb today announced Phase 2b results for risdiplam in patients with non-small cell lung cancer. The study demonstrated that risdiplam improves quality of life compared to standard of care or placebo. These results provide important insights into the treatment of non-small cell lung cancer and support the continued development of risdiplam in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.